A Study of Isoprinosine in Patients With Severe AIDS

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): * Comparison of total helper and suppressor T-cell numbers among the groups. * Comparison of changes in natural killer cell activity. * Comparison of other laboratory findings among the groups. Clinical changes: * Comparison of the frequency of opportunistic infections among the groups. * Comparison of the frequency of the development of AIDS-related malignancies. * Comparison of other clinical manifestations relative to severity and time of onset.

Key facts

Study ID

NCT00002295

Run by

Newport Pharmaceuticals International

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Co-existing Condition:
• Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded.
• Concurrent Medication:
• Excluded:
• Steroids.
• Cytotoxic immunosuppressive agents.
• Radiotherapy.
• The following are excluded:
• Critically ill patients.
• Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.
• Patients who have received any other immunotherapy.
• Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer.
• Prior Medication:
• Excluded:
• Any other immunotherapy.
• Patients with severe AIDS and specified laboratory immunologic defects.

Where it is running

• Newport Pharmaceuticals International Inc — Laguna Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.